Angie Wirick
About Angie Wirick
Angie Wirick serves as the Chief Financial Officer at AtriCure, Inc., where she has been instrumental in financial strategies supporting the FDA approval of key medical devices. With a background in accounting and extensive experience in financial planning, she has contributed to the company's global expansion and product development initiatives.
Current Role at AtriCure
Angie Wirick serves as the Chief Financial Officer at AtriCure, Inc., a position she has held since 2020. In this role, she oversees the financial operations of the company, ensuring alignment with its strategic goals. Her leadership in financial strategy has been pivotal in supporting key initiatives, including the FDA approval of innovative medical devices.
Previous Experience at AtriCure
Prior to her current role, Angie Wirick held several positions at AtriCure, Inc. She served as Vice President of Finance from 2016 to 2020 and as Director of Finance from 2014 to 2016. During her tenure, she contributed to financial planning and analysis that facilitated the global expansion of AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products and managed financial operations for the development of the cryoICE cryoSPHERE® probe.
Education and Expertise
Angie Wirick studied at the University of Dayton, where she earned a Bachelor of Science (B.S.) in Accounting from 1995 to 1999. Her educational background provides a strong foundation for her expertise in financial management within the medical device industry.
Early Career at Arthur Andersen & Co.
Before joining AtriCure, Angie Wirick worked at Arthur Andersen & Co. as a Senior and Staff Accountant from 1999 to 2002 in Cincinnati, Ohio. This early experience in accounting laid the groundwork for her subsequent roles in financial leadership.
Involvement in Key Projects
Angie Wirick has been involved in the financial oversight of several significant projects at AtriCure, including the Hybrid AF™ Therapy, which provides a minimally invasive solution for patients with long-standing persistent Afib. Her contributions have supported the company's mission to innovate in the field of cardiac care.